One strategy to improve efficacy is finding novel targets and designing constructs targeting more than one antigen, such as the dual-targeting CD19/CD22 CAR in B-cell malignancies [24,25,26], dual CD19/CD20 CAR in lymphomas and leukemia [27,28], and CD19/BCMA-specific CAR in MM [29]. This evidence concerns the gene CD19 and Miyoshi myopathy.